Medical Condition News

RSS

Bluhm Cardiovascular Institute implants two Heartware ventricular assist devices

The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. This is the first time that two Heartware VADs have been implanted in the left and right ventricles anywhere in North America—a "game changer" in the realm of heart assist devices according to Patrick M. McCarthy, MD, chief of the hospital's division of cardiac surgery and director of the hospital's Bluhm Cardiovascular Institute.

11 Aug 2010

Cord Blood America to begin sale of DNA Predisposition testing services

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that within 90 days it will begin selling DNA Predisposition testing services in conjunction with The DNA Shop, LLC,Henderson, Nevada.

11 Aug 2010

Common soluble proteins become insoluble and form aggregates while aging: Study

In neurodegenerative diseases, clumps of insoluble proteins appear in patients' brains. These aggregates contain proteins that are unique to each disease, such as amyloid beta in Alzheimer's disease, but they are intertwined with small amounts of many other insoluble proteins that are normally present in a soluble form in healthy young individuals. For years, these other proteins were thought to be accidental inclusions in the aggregates, much as a sea turtle might be caught in a net of fish.Now, in a surprising new finding, researchers at the University of California, San Francisco, report that many of the proteins present as minor components of disease aggregates actually clump together as a normal part of aging in healthy individuals.

11 Aug 2010

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.

11 Aug 2010

Researchers identify perforant path brain passage associated with Alzheimer's disease

With the help of volunteers aged 18 to 89, UC Irvine researchers have identified for the first time in humans a long-hidden part of the brain called the perforant path. Scientists have struggled for decades to locate the tiny passage, which is believed to deteriorate gradually as part of normal aging and far more quickly due to Alzheimer's disease.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

Acute aortic dissection program reduces diagnosis time in AAD patients

Using a standardized protocol within a regional health network, a multidisciplinary acute aortic dissection (AAD) program resulted in a 43 percent reduction in time to diagnosis for all AAD patients over the course of five years, based on study results published in the July edition of Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

11 Aug 2010

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.

11 Aug 2010

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Detection of malignant melanoma, the most serious type of skin cancer, will soon be quicker and easier thanks to the work of researchers at Missouri University of Science and Technology.The research, which is funded by the National Institutes of Health, recently received a patent titled "Automatic Detection of Critical Dermoscopy Features for Malignant Melanoma Diagnosis." The patent applies to a method for computer-aided analysis of photographs of skin lesions to detect the cancer. Melanoma can be cured if it is diagnosed early enough.

11 Aug 2010

Georgia Institute receives EUREKA grant to design brain tumor treatment

The Georgia Institute of Technology has received a EUREKA grant from the National Institutes of Health (NIH) to design a new way to treat invasive brain tumors by capturing the migrating cells that spread the disease. The EUREKA -- Exceptional, Unconventional Research Enabling Knowledge Acceleration -- program helps scientists test new, unconventional ideas or tackle major methodological or technical challenges.

11 Aug 2010

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.

11 Aug 2010

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Along with skeletal muscles, it may be important to monitor heart function in patients with spinal muscular atrophy (SMA). These are the findings from a study conducted by Nationwide Children's Hospital and published online ahead of print in Human Molecular Genetics. This is the first study to report cardiac dysfunction in mouse models of SMA.

11 Aug 2010

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).

11 Aug 2010

Acoustic cardiography improves diagnostic accuracy in acute heart failure

It allows them to hear the S3, an abnormal third sound in the heart's rhythm strongly associated with cardiac disease and heart failure. However, the low-frequency, low-pitch sound is notoriously very difficult to hear with a stethoscope alone.It allows them to hear the S3, an abnormal third sound in the heart's rhythm strongly associated with cardiac disease and heart failure. However, the low-frequency, low-pitch sound is notoriously very difficult to hear with a stethoscope alone.

11 Aug 2010

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.

11 Aug 2010

Education, changes in reimbursement practices can reduce inappropriate antibiotic usage: Study

Improved drug coverage under Medicare Part D has led to an increase in the use of antibiotics by seniors, particularly of brand-name and more expensive drugs, according to a University of Pittsburgh Graduate School of Public Health study. Published in the Aug. 23 issue of Archives of Internal Medicine and the first to explore spending on antibiotics under Medicare Part D, the study suggests recent changes in drug coverage improved the use of antibiotics for pneumonia, but could lead to unnecessary spending on expensive broad-spectrum antibiotics and the overuse of inappropriate antibiotics.

11 Aug 2010

Smile Pink campaign encourages women, men to support early breast cancer testing

Over five hundred dentists from around the United States have joined forces in an exciting new initiative aimed at promoting early detection in breast cancer. Dubbed "Smile Pink", the campaign encourages women and men to show their support of early breast cancer testing by adding a stylish Pink Swarovski Crystal to their smile.

11 Aug 2010

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.

11 Aug 2010

Scientists develop new method to enable drug release inside cancer cells

Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.The new system - the first to utilize a class of porous nanomaterials driven by a magnetic core - has the potential to improve both targeted drug-delivery and magnetic resonance imaging in the treatment of cancer and other diseases.

11 Aug 2010

Study suggests zinc supplementation may reduce pneumonia risk

A high proportion of nursing facility residents were found to have low serum (blood) zinc concentrations during an observational study funded by the Agricultural Research Service (ARS) and the National Institute of Aging. The scientists found that those with normal blood zinc concentrations were about 50 percent less likely to develop pneumonia than those with low concentrations.

11 Aug 2010

Medical Condition News

Bluhm Cardiovascular Institute implants two Heartware ventricular assist devices

Cord Blood America to begin sale of DNA Predisposition testing services

Common soluble proteins become insoluble and form aggregates while aging: Study

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Researchers identify perforant path brain passage associated with Alzheimer's disease

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Acute aortic dissection program reduces diagnosis time in AAD patients

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Georgia Institute receives EUREKA grant to design brain tumor treatment

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Spinal muscular atrophy may lead to cardiac dysfunction: Study

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Acoustic cardiography improves diagnostic accuracy in acute heart failure

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

Education, changes in reimbursement practices can reduce inappropriate antibiotic usage: Study

Smile Pink campaign encourages women, men to support early breast cancer testing

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Scientists develop new method to enable drug release inside cancer cells

Study suggests zinc supplementation may reduce pneumonia risk

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News